BPC-157 for Sale: Understanding Purity, COAs, and Lab-Grade Standards

Search for “BPC-157 for sale” and you will find a market with price points that range from a few dollars per milligram on wholesale chemical directories to nearly $400 for a single 10 mg vial from domestic suppliers. The spread is not explained by the cost of the raw material. It is explained by differences in sourcing, testing, documentation, and the degree to which each seller is willing to be transparent about what is actually in the vial.

This guide is written for laboratory researchers who need to evaluate a BPC-157 supplier before placing an order. It covers what the published literature says about the compound, how the FDA and anti-doping authorities treat it, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.

What BPC-157 is, and what the research actually shows

BPC-157 is a synthetic pentadecapeptide, meaning it is composed of 15 amino acids. The sequence is derived from a portion of human gastric juice protein known as body protection compound. The synthetic version used in research is designed to match the amino acid sequence of the naturally occurring fragment.

The compound has been studied extensively in preclinical models. A systematic review published in HSS Journal in 2025 examined the emerging use of BPC-157 in orthopaedic sports medicine. The review found that BPC-157 was the most frequently represented peptide agent in musculoskeletal research, with preclinical studies describing effects on tendon healing, ligament repair, muscle regeneration, and inflammatory modulation. The authors note that the evidence base is primarily preclinical, and that there are no human clinical trials establishing efficacy for any diagnosis or treatment.

That distinction matters. The research on BPC-157 is dominated by animal models. The compound has been investigated for inflammatory bowel disease and soft tissue healing in animal studies, but published human clinical trial data is lacking. USADA’s athlete guidance on BPC-157 states plainly that there are no human clinical trials establishing efficacy for any diagnosis or treatment, and that because the compound has not been extensively studied in humans, it is unknown whether there is a safe dose.

For researchers, the absence of human data is not a reason to avoid studying the compound. It is a reason to be precise about what the literature does and does not support, and to source material that has been analytically verified so that experimental results can be traced to a known input.

Why the FDA considers BPC-157 a safety risk

BPC-157 is not an approved drug in the United States. It has not received authorization from the FDA, the European Medicines Agency, or any other national regulatory body for human use. What distinguishes BPC-157 from some other unapproved research peptides is that the FDA has taken specific regulatory action regarding its use in compounding.

The FDA’s page on bulk drug substances that may present significant safety risks places BPC-157 in Category 2. Category 2 substances are those the agency has identified as presenting potential significant safety risks when used in compounding. The FDA’s concerns regarding BPC-157 include the potential for immunogenicity, meaning the possibility that the peptide could trigger an immune response. The agency has also stated that there is limited safety-related information available and that it lacks sufficient information to know whether the drug could cause harm when administered to humans.

What this means in practice is that BPC-157 cannot legally be compounded by 503A or 503B pharmacies under current FDA policy. The agency’s briefing document for the Pharmacy Compounding Advisory Committee notes that the extent of any compounding use was unclear or unknown, and that the agency found insufficient evidence of effectiveness to support inclusion on the 503A bulk drug substances list. In July 2026, the PCAC voted in favor of adding BPC-157 to the list of bulk drug substances that can be used in compounding under Section 503A, a recommendation that is now under FDA review.

For researchers, the practical implication is that the regulatory environment around BPC-157 is unsettled. A supplier that claims the compound is legal to sell for human use is misrepresenting the current regulatory posture. A supplier that sells it as a research-use-only chemical and provides analytical documentation is operating within a recognized research supply channel.

Why BPC-157 is banned in sport

BPC-157 is prohibited at all times under the World Anti-Doping Agency’s Prohibited List in the category of S0 Non-Approved Substances. USADA explains that S0 covers substances that are not approved by any government regulatory authority and are not approved for human use. Because of their potential to enhance performance, they are prohibited, and no therapeutic use exemption is available for BPC-157.

USADA has issued sanctions for BPC-157 use. In September 2025, triathlete Anthony McCauley accepted a four-year suspension after testing positive for BPC-157, TB-500, CJC-1295, and ipamorelin. USADA’s announcement stated that these peptides are not approved for human clinical use and that their use poses significant health risks for athletes.

The anti-doping context is relevant to researchers because it speaks to the compound’s biological activity. A substance does not end up on the S0 list unless it has demonstrated the potential to enhance performance or pose a health risk. For laboratory researchers, the anti-doping designation is a signal that the compound interacts with biological systems in ways that warrant careful study, not a reason to dismiss it as inert.

The researcher’s BPC-157 sourcing checklist

The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.

1. Lot-specific certificate of analysis, not a generic sample

A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. A supplier that shows a single COA for “BPC-157” without tying it to a lot number is showing you marketing material, not a laboratory report. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.

Stack Research publishes a lot-specific report for each configuration of its BPC-157 research peptide. The current lot documentation for the 10 mg configuration shows HPLC purity of 98.2 percent, measured content of 11.13 mg, and passing results for identity, bacterial endotoxin, and sterility. The report identifies the testing laboratory as Accumark Labs and includes a report ID that can be cross-referenced. The product page shows the exact SKU, lot number, laboratory, report ID, and sample dates alongside the price.

2. What the COA actually tests

A certificate that lists only “purity: 98%” is incomplete. The useful fields are identity, purity by HPLC, measured content, endotoxin, and sterility. Identity confirms the peptide sequence matches the reference standard. Purity by HPLC shows the percentage of the sample that is the target compound. Measured content tells you how much peptide is actually in the vial, which can differ from the label. Endotoxin and sterility results speak to the handling conditions.

If a supplier’s COA omits measured content or endotoxin, that is a gap. It may not be a dealbreaker for every research context, but it is a data point about how thoroughly the supplier tests its material.

3. The research-use-only boundary

Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is a legal boundary, not a suggestion.

What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. That combination is what the FDA has cited in warning letters. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.

4. Pricing and configuration transparency

BPC-157 vials are typically sold in 5 mg and 10 mg configurations. The price per milligram should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 10 mg BPC-157 vial at $89.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price, which makes the listing auditable.

5. The regulatory context around the compound

Researchers studying BPC-157 should be aware that the FDA has placed it in Category 2 of bulk drug substances that may present significant safety risks when used in compounding. The FDA’s compounding safety page provides the current list and the reasoning behind each inclusion. This is not a restriction on laboratory research, but it is context that shapes how the compound is discussed in regulatory and clinical settings.

How Stack Research approaches BPC-157 documentation

Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.

The BPC-157 product page shows the current lot report directly on the page, with the purity, measured content, endotoxin, and sterility results visible without requiring a separate download. The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.

That last point is worth emphasizing because it is the dividing line the FDA has drawn in its enforcement actions. A supplier can sell research peptides and publish analytical documentation without crossing into human-use marketing. When a supplier stays on the research side of that line, the documentation becomes the primary basis for evaluating the product. When a supplier crosses the line, the documentation is no longer the main thing being sold.

Comparing BPC-157 documentation standards

The table below outlines the documentation elements that separate a transparent listing from an incomplete one. It is not a ranking of suppliers but a framework for evaluating any listing you encounter.

The table is not a guarantee. A supplier can produce all of these documents and still be selling a product that does not match the report, which is why independent testing services exist. But a supplier that cannot produce the documents at all is not worth the time it takes to evaluate further.

Common questions researchers ask before buying BPC-157

Is BPC-157 legal to buy for research purposes?

BPC-157 is not an approved drug, so it cannot be legally sold as a medicine. Research peptides labeled for laboratory use occupy a different regulatory space, but the FDA has placed BPC-157 in Category 2 of bulk drug substances that may present significant safety risks when used in compounding. Researchers should purchase only from suppliers that maintain the research-use boundary and provide analytical documentation.

What purity should a BPC-157 COA show?

Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. Many suppliers report 98 to 99 percent or higher. The purity figure is only meaningful alongside identity and content results. A vial can be 98 percent pure and still contain less peptide than the label claims if the fill is off.

How do I verify that a COA is real?

Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If a supplier cannot tell you which laboratory performed the test, the COA cannot be independently verified.

What is the difference between BPC-157 and BPC-157 acetate?

BPC-157 can be supplied in free-base form or as an acetate salt. The acetate form is more stable and is the form most commonly sold as a research peptide. The COA should specify which form the vial contains. Researchers should confirm the identity of any product by its COA, not by the brand name on the vial.

What should I do if a supplier’s listing makes health claims?

Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the peptide “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.

Can I compare BPC-157 documentation across suppliers?

Yes, and you should. The relevant fields are comparable across suppliers: purity, identity, measured content, endotoxin, sterility, and lot traceability. The guide to reading a certificate of analysis walks through each field and explains what a complete report should contain.